Trial Profile
A study to evaluate the effect of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in patients with metastatic colorectal cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Apr 2016 New trial record